15 results about "Heart cells" patented technology

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

The invention provides application of a TP receptor inhibitor in preparation of a medicine for treating cardiac fibrosis, and relates to the technical field of biomedicine. According to the application, the key effect of the TP receptor in heart Gli1 + cells is defined, the TP receptor is determined as an anti-fibrosis specific drug target, and the limitation of insufficient targeting of the existing therapy is broken through. By inhibiting a TP receptor, an AMPK signal channel can be effectively activated, and then ubiquitination degradation of a fibrosis-promoting key factor Gli1 protein is promoted, so that generation and activation of myofibroblasts are inhibited from the source, and the fibrosis process is accurately intervened.

The application relates to recombinant adeno-associated virus particles comprising variant AAV capsid proteins (e.g., variant capsid proteins of serotype AAVrh74, AAVrh10, AAV8, or AAV1). Recombinant adeno-associated virus particles of the disclosure can be used to deliver exogenous nucleic acids (e.g., nucleic acids comprising genes encoding therapeutic RNAs or therapeutic proteins) to target cells, such as heart cells. In some aspects of the disclosure, the variant capsid proteins that comprise amino acid variations that alter the binding activity of recombinant adeno-associated virus particles to target cells, such as by increasing binding to heart cells and / or decreasing binding to liver cells. In some embodiments, the recombinant adeno-associated virus particles are utilized in a method of treating subject. In some embodiments, such methods are utilized in delivering exogenous nucleic acids to target cells more specifically and / or at lower doses compared to other recombinant adeno-associated particle delivery systems.

The application discloses application of SFRP3 in prevention and treatment of dilated cardiomyopathy, and belongs to the technical field of biological medicine. The application down-regulates SFRP3 expression in myocardial cells by means of gene interference, RNA interference technology, antibody or small molecule inhibitor, etc. to treat dilated cardiomyopathy, realizes the purposes of improving heart function, reducing cardiac dilatation, improving myocardial fibrosis and effectively promoting myocardial repair, and provides a more effective and low-side-effect treatment method for treatment of dilated cardiomyopathy. The treatment idea provided by the application can not only relieve symptoms of dilated cardiomyopathy, but also regulate physiological processes of heart cells at a molecular level, and provides a new idea for clinical treatment of dilated cardiomyopathy.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

Methods and systems for cardiomyocyte maturation are generally described. In some embodiments, immature cardiomyocytes may be incubated with a three-dimensional matrix in an incubation medium and permitted to mature over a period of several weeks. In some embodiments, the three-dimensional matrix may include at least one population of microcarriers. The systems for cardiomyocyte maturation are evaluated for their scalability to meet large-scale global demand for cardiac cell therapies.

This disclosure relates generally to methods of screening and preparing high purity cardiac cell therapies and related cell preparations.

A medical tool testing apparatus comprising a vessel. The vessel comprises a scaffold formed from biomaterial, live cardiac tissue, generated from cardiac cells, proliferating on the scaffold, the live cardiac tissue configured to generate electrical activity. The vessel also comprises a medical tool, in contact with live cardiac tissue, used for a medical procedure within patient anatomy. Operational features of the medical tool are determined by a visually perceptible condition of the live cardiac tissue.

This invention relates to the field of cardiac electrophysiological simulation technology, specifically to simulation methods, devices, equipment, and media for analyzing ventricular arrhythmias. The invention first sets the ion channel conductivity parameters of the heart under pathological conditions, then calculates the total ion current generated by the lesion based on these parameters, and simultaneously sets the myocardial tissue conductivity caused by the lesion. The cardiac geometry, initial membrane potential, and the set ion channel conductivity parameters, total ion current, and myocardial tissue conductivity are substituted into a Bidomain model to solve for the cardiac transmembrane potential and intracellular / extracellular potential. Based on these potentials, the invention analyzes whether the aforementioned lesions will induce ventricular arrhythmias. This invention has the ability to simulate a wide range of pathological scenarios, effectively reducing the limitations of existing medical diagnostic methods in analyzing the mechanisms of arrhythmia.

The present invention provides an artificially designed novel NRG-1 nucleic acid molecule, a protein variant thereof, a vector, a vaccine, a cell, a pharmaceutical composition, and a protein composition. Also provided are a method for using the product to produce a protein and a primary RNA polynucleotide, and a use in preparation of a product for preventing, alleviating or treating cardiovascular diseases and neurological diseases, a product for maintaining normal functions of heart cells or tissues, and a vaccine.

The disclosure generally relates to methods, cells, and compositions for preparing cardiac extracellular matrix. In particular, provided herein are methods for preparing a cardiac extracellular matrix using SUSD2 High fibroblasts and SUSD2 High myofibroblasts.

The invention provides a multifunctional epicardial attaching device. The device comprises a hydrogel adhesion layer, a porous support layer and a conductive thin film layer which are sequentially arranged from bottom to top; wherein the surface of the hydrogel adhesion layer is provided with a plurality of biological ceramic spines arranged in an array, the biological ceramic spines penetrate through epicardial tissue to detect the ion concentration of heart cells in real time, and the hydrogel adhesion layer and the epicardial tissue are fixedly attached; the porous support layer is used for supporting the hydrogel adhesion layer and the conductive film layer, and the conductive film layer is electrically connected with the biological ceramic spines and used for converting the ion concentration detected by the biological ceramic spines into electric signals and transmitting the electric signals to in-vitro monitoring equipment; a micro cavity is formed in the porous bracket layer, and a first functional sheet and a second functional sheet are arranged in the micro cavity; the first functional piece and the second functional piece can be contacted and separated along with heartbeat and generate electric signals. According to the scheme, long-term, stable, continuous and real-time monitoring of the physiological parameters of the heart can be achieved.

This invention discloses a method for extracting interstitial fluid from cardiac tissue, belonging to the field of biomedical technology. Based on the unique characteristics of the heart, a organ closely related to blood circulation, and its differences in tissue physical properties compared to other organs, this invention designs and develops this extraction method, which specifically includes: rinsing isolated cardiac tissue with pre-cooled physiological saline; low-speed centrifugation to remove residual rinsing fluid from the heart; and centrifugation again to obtain interstitial fluid from the cardiac tissue. Comparison of the obtained interstitial fluid with cardiac cell fluid and serum confirms the accuracy and specificity of the extraction scheme of this invention. The centrifugation process of this invention does not damage cells, preserving its unique differences from serum and cardiac cell fluid. The extracted interstitial fluid has a high protein concentration, which can better reflect changes in the cardiac microenvironment, facilitating subsequent related medical and basic research.